An observational study focusing on the changes of the upper eyelid sulcus after switching from FP receptor agonist to EP2 receptor agonist

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 14 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

01 Jan 2023 Results(n=23) assessing Prostaglandin-Associated Periorbitopathy Symptom Alleviation After Switching Prostaglandin F Receptor Agonist to EP2 Receptor Agonist in Patients with Glaucoma published in the Journal of Ocular Pharmacology and Therapeutics
01 Sep 2021 Interim Results of 3-month follow-up assessing effects of omidenepag isopropyl treatment on deepening of the upper eyelid sulcus caused by FP receptor agonists, published in the Japanese Journal of Ophthalmology
15 May 2019 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com